2-(6-Chloropyridin-3-yl)-2-methylpropanenitrile, 98%, 1g

Methyl 3-methyl-1H-indazole-5-carboxylate, 95.0%, 250mg

Monoethyl Itaconate>97.0%(GC)(T)25g

Plan PLPHi 10x/0.25 phase contrast IOS infinity corrected objective

6-(2-(Methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynamide, 98.0%, 1g

Benzyl (4-(hydroxymethyl)phenyl)carbamate, 98%, 1g

Kryptofix 11 aza, 95.0%, 5g

(S)-2-(pyrrolidin-1-yl)propan-1-ol, 97%, 10g

5-[(2-Amino-1,3-thiazol-4-yl)methyl]-N-methyl-1,3,4-thiadiazol-2-amine, 95.0%, 5g

N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-S-((4-methoxyphenyl)diphenylmethyl)-D-cysteine, 97%, 5g

2-(2-Bromo-5-methoxyphenyl)acetonitrile, 95.0%, 1g

(R)-4-Benzyl-3-(3-methylbutanoyl)oxazolidin-2-one, 95.0%, 1g

3-{3-[(tert-Butoxycarbonyl)amino]phenyl}propanoic acid, 95.0%, 250mg